During the M.S. period, Dr. Chen majored in Pharmaceutics in Dr. Zheng’s
lab, where she had been focusing on biomaterials and drug delivery system.
She worked at a pharmaceutical company for about 2 years after graduation,
further strengthening her knowledge on biochemistry and drug development.
Encouraged by the striking progress of bioengineering and its promising
impact on drug development, she went to Japan and pursued her PhD degree in
Dr. Kadomatsu’s lab on molecular biology. She focused on two projects. One
was on Basigin/CD147 knock out mice. She clearly elucidated the effect of
flanking genes and genetic background on the phenotype, and provided a
useful means of investigating the biological function of Basigin. The other
study was on Midkine (MK, a heparin binding growth factor) mediated signal
transduction and its impact on cancer treatment. She continued this study
in Dr. Kadomatsu’s lab as research fellow for another 2 years after
graduation. Using a small Trapping Peptide (MK binding domain in its
receptor), she successfully demonstrated the crucial role of MK-LRP1
signaling in anchorage-independent cell growth. She also worked on several
MK projects including its biosynthesis, its roles in angiogenesis, cardiac
ischemia as well as in childhood leukemia.
After that, Dr. Chen joined Dr. Steven P. Balk’s lab in BIDMC and continued
her research on cancer biology. She has been focusing on the signal pathway
and molecular mechanism involved in prostate cancer. She undertook the
study on mechanisms that contribute to PI3 kinase activation in PTEN
deficient prostate cancer cells. She found that the p110beta isoform of PI3
kinase was mediating basal activity independent of RTK, while the p110alpha
mediated GF stimulated activation. She has also been studying the function
of a non-receptor kinase termed Bmx, which is activated downstream of PI3
kinase and contributes to prostate cancer development. Using a positional
scanning peptide library screen, she has identified that Bmx has a marked
preference for substrates with a priming phosphotyrosine at -1 position,
and further validated that Bmx phosphorylates multiple tyrosine kinases on
their kinase domain and regulates their activity, which will have great
implications for many cancers as well as metabolic diseases such as type 2
diabetes. She has also successfully developed a mouse prostate cancer model
with inducible ERG expression in prostate. Given that TMPRSS2-ERG
rearrangement occurs almost in half of the prostate cancer patients, this
model will definitely be useful for elucidating the function mechanism of
ERG on prostate cancer and contributing to the prostate cancer treatment.
Meanwhile, she collaborates with other colleagues and contributes to
understanding the molecular mechanism on castration resistance prostate
cancer (CRPC), including intratumoral de novo androgen synthesis,
AR-mediated gene expression, sox9 gene mediation in TMPRSS2:ERG positive
prostate cancer, AR mediated p27 degradation as well as AR targeting drug
Email Dr. Chen
Research Fellow, Beth Israel Deaconess Medical Center / Harvard Medical
School, Boston, MA: 2008-present
Global COE Research Fellowship, Nagoya University, Japan: 2005-2008
Global COE Research Assistantship, Nagoya University, Japan: 2003-2005
Postdoctoral Training: Cancer Biology, Beth Israel Deaconess Medical
Center, US: 2008-present
Postdoctoral Training: Medical Science, Nagoya University, Japan: 2005-2008
Ph.D.: Medical Science, Nagoya University, Japan: 2001-2005
M.S.: Pharmaceutics, Shenyang Pharmaceutical University, China: 1994-1997
B.S.: Pharmaceutics, Shenyang Pharmaceutical University, China: 1990-1994
Grants and Awards
JSPS Young Researcher Scholarship, Nagoya University, Japan: 2001-2002
LiaoNing Province Education Committee Scientific Technology Promotion Award
for Junior Researcher: 1998
F. Ma, H. Ye, H. H. He, S. J. Gerrin, S. Chen,
B. Tanenbaum, C. Cai, A. G. Sowalsky, L. He, H. Wang, S. P.
Balk, and X. Yuan. SOX9 drives WNT pathway activation in
prostate cancer . J Clin Invest. 2016;126(5):1745-1758.
doi:10.1172/JCI78815. Epub 2016 Apr 4.
Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O,
Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai
C. ErbB2 Signaling Increases Androgen Receptor Expression in
Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016
Mar 2. [Epub ahead of print]PMID: 26936914
, Cai C, Simon NI, Yuan X, Gray NS, Balk SP. (2014) Bmx mediates
CRPC growth through regulating multiple RTK. (In Preparation)
Yu Z, Chen S, Sowalsky AG, Voznesensky OS,
Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid Induction of
Androgen Receptor Splice Variants by Androgen Deprivation in
Prostate Cancer (2014). Clin Cancer Res. 20(6):1590-1600.
Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu
H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J,
Look AT, Griffin JD, Balk SP*, Liu Q*, and Gray NS*. (2013)
Discovery of a Selective Irreversible BMX Inhibitor for
Prostate Cancer. ACS Chemical Biology
Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
Androgen receptor functions in castration-resistant prostate
cancer and mechanisms of resistance to new agents targeting the
androgen axis (2013). Oncogene. Jun
10. doi: 10.1038/onc.2013.235.
, X. Jiang, C. A. Gewinner, J. M. Asara, N. I. Simon, C. Cai,
L. C. Cantley, S. P. Balk, Tyrosine Kinase BMX Phosphorylates
Phosphotyrosine-Primed Motif Mediating the Activation of
Multiple Receptor Tyrosine Kinases. Sci. Signal. 6, ra40 (2013).
Cai C, Wang H, He HH, Chen S, He L, Ma F,
Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M,
Balk SP & Yuan X. (2013) ERG Induces Androgen
Receptor-mediated Regulation of SOX9 in Prostate Cancer. ( Journal of Clinical Investigation)
Shen H, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP & Rigby AC. (2012) In
Silico Discovery of Androgen Receptor Antagonists with Activity
in Castration Resistant Prostate Cancer. ( Molecular Endocrinology).
Wang H, Xu Y, Fang Z, Chen S, Balk SP and Yuan
X. (2012) Doxycycline Regulated Induction of AKT in Murine
Prostate Drives Proliferation Independently of p27 Cyclin
Dependent Kinase Inhibitor Downregulation. ( PLOS One). 7(7): e41330
Fang Z, Zhang T, Dizeyi N, Chen S, Wang H,
Swanson KD, Cai C, Balk SP and Yuan X. (2012) Androgen Receptor
Enhances p27 Degradation in Prostate Cancer Cells Through Rapid
and Selective TORC2 Activation. The Journal of Biological Chemistry.
Cai C, He HH, Chen S, Coleman I, Wang H, Fang
Z, Chen S, Nelson PS, Liu XS, Brown M, and Balk SP. (2011)
Androgen receptor gene expression in prostate cancer is
directly suppressed by the androgen receptor through
recruitment of lysine specific demethylase 1. Cancer Cell. 20(4):457-71.
Cai C, Chen S, Ng P, Mostaghel EA, Marck B,
Matsumoto AM, Simon, NI, Wang H, Chen S, and Balk SP. (2011)
Intratumoral de novo steroid synthesis activates androgen
receptor in castration resistant prostate cancer and is
upregulated by treatment with CYP17A1 inhibitors. Cancer Research. 71(20):6503-13.
Sakamoto K, Bu GJ, Chen S, Takei Y, Hibi K, Kodera
Y, McCormick LM, Nakao A, Noda M, Muramatsu T, and Kadomatsu K.
(2011) Premature Ligand-Receptor Interaction during Biosynthesis
Limits the Product in of Growth Factor Midkine and Its Receptor LDL
Receptor-related Protein 1. The Journal of Biological Chemistry.
Jiang XN, Chen S, Asara JM, and Balk SP. (2010)
Phosphoinositide 3-Kinase Pathway Activation in Phosphate and
Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is
Independent of Receptor Tyrosine Kinases and Mediated by the p110
beta and p110 delta Catalytic Subunits. The Journal of Biological Chemistry.
Narita H, Chen S, Komori K, and Kadomatsu K.
(2008) Midkine is expressed by infiltrating macrophages in in-stent
restenosis in hypercholesterolemic rabbits. Journal of Vascular Surgery. 47(6):
, Bu G, Takei Y, Sakamoto K, Ikematsu S, Muramatsu T, and Kadomatsu
K. (2007) Journal of Cell Science. 120(Pt
Hidaka H, Yagasaki H, Takahashi Y, Hama A, Nishio N, Tanaka M,
Yoshida N, Villalobos IB, Wang Y, Xu Y, Horibe K, Chen S, Kadomatsu K, and Kojima S. (2007)
Increased midkine gene expression in childhood B-precursor acute
lymphoblastic leukemia. Leukemia Research. Aug 31(8):1053-1059.
Horiba M, Kadomatsu K, Yasui K, Lee JK, Takenaka H, Sumida A,
Kamiya K, Chen S, Sakuma S, Muramatsu T, and
Kodama I. (2006) Midkine plays a protective role against cardiac
ischemia/reperfusion injury through a reduction of apoptotic
reaction. Circulation .
, Kadomatsu K, Kondo M, Toyama Y, Toshimori K, Ueno S, Miyake Y,
Muramatsu T. (2004) Effects of flanking genes on the phenotypes of
mice deficient in basigin/CD147.
Biochemical and Biophysical research communications.
, and Zheng J. (2000) The observation on in vitro permeation and
Irritation of Nimodipine Paches.
Journal of Shenyang Pharmaceutical University.
, Zheng J, Hao J, and Wu H. (1999) Effect of Penetration Enhancers
and Iontophoresis on Nimodipine in Vitro Permeation.
Journal of Shenyang Pharmaceutical University.
Pharmaceutical Coating Technology (Chinese Version Translation)
(2001) (Original Author: Graham Cole, John Hogan, Michael Auton). China Medical Technology Press. ISBN:
Dermal and Transdermal delivery system (1997 original version; 2006
modified new version) People’s Health Press. ISBN:
Link to Dr. Chen's Harvard Catalyst Page